CN104306416A - Medicine for treating bronchitis, pneumonia and asthma and preparation method thereof - Google Patents
Medicine for treating bronchitis, pneumonia and asthma and preparation method thereof Download PDFInfo
- Publication number
- CN104306416A CN104306416A CN201410556463.6A CN201410556463A CN104306416A CN 104306416 A CN104306416 A CN 104306416A CN 201410556463 A CN201410556463 A CN 201410556463A CN 104306416 A CN104306416 A CN 104306416A
- Authority
- CN
- China
- Prior art keywords
- sinensis
- volatile oil
- medicine
- asthma
- pneumonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a medicine for treating bronchitis, pneumonia and asthma and a preparation method thereof. The medicine is prepared by mixing ivy volatile oil and ivy saponin in a volume mass ratio of 1:(40-100). The preparation method comprises the following steps: (1) preparing ivy volatile oil; (2) preparing ivy saponin; (3) preparing an effective part ingredient, namely preparing the effective part ingredient from the ivy volatile oil and the ivy saponin; (4) preparing a soft capsule or an oral solution for treating bronchitis, pneumonia and asthma. The preparation method is simple, convenient and reliable, and is convenient for formulation of the Chinese patent medicine quality standard and quality control standard in production, and is advantageous to quality monitoring and large-scale production of Chinese patent medicine products; cilia, possibly causing adverse response, on ivy leaves can be removed, so that adverse response after the medicine is taken can be reduced and eliminated; animal tests prove that the prepare medicine has a positive effect on treatment of bronchitis, pneumonia and asthma.
Description
Technical field
The invention belongs to Chinese patent medicine and preparing technical field thereof, relate to the extraction purification of effective ingredient in Chinese, be specifically related to a kind ofly treat medicine of bronchitis, pneumonia and asthma and preparation method thereof.
Background technology
Bronchitis, pneumonia and asthma all belong to common respiratory tract disease, and their cardinal symptom has heating, headache, nasal obstruction, rhinorrhea, pharyngalgia, cough etc.The traditional Chinese medical science is thought, bronchitic pathogenesis is diseases caused by exogenous pathogenic factor and internal injury, and diseases caused by exogenous pathogenic factor are six climate exopathogens exopathogen invasion and attack lung systems, and internal injury is mainly caused by visceral dysfunction.Pneumonia is often because the heresy of wind heat or the heresy of wind and cold enter caused by inner heat-transformation.Asthma is because of exopathogen invasion and attack, the heresy of wind and cold, invasion and attack flesh table, internal resistance in lung, cold-evil's closing fur, lung qi loses respectful falling; Or because of in wind heat, lung-heat stops up Sheng, and clear respectful dereliction of duty or lung have intrinsic heat, and again by cold-evil is restrainted, heat must not be let out, caused by abnormal rising of lung-QI.In recent years, because industrial pollution causes environment for human survival Air Contamination more serious, cause respiratory tract disease prevalence to remain high and have the trend increased year by year, not only the populous of respiratory tract disease is suffered from by China, one of the World Health Organization's four large diseases chronic respiratory tract disease being classified as harm humans health.
Caulis Hederae Sinensis (Hedera nepalensis var. sinensis), it is Araliaceae Hedera plant, originate in Europe, Asia and north African, it can absorb the harmful substance in air by the Minute pores on blade, and it is converted into harmless sugared part and aminoacid, therefore, Caulis Hederae Sinensis effectively can resist the carcinogen in nicotine, can remove formaldehyde.Record according to China supplement to the Herbal: Caulis Hederae Sinensis have dispel the wind, dampness removing, suppressing the hyperactive liver, removing toxic substances effect, be usually used in treating rheumatic arthritis in the Chinese traditional treatment of China.Saponin is one of principle active component of Caulis Hederae Sinensis, is also studied maximum element of the first species in Hedera plant.Hederagenin is disaccharidase chain Hederagenin C(Hederacoside C), its molecular formula is C
59h
960
26, molecular weight 1221.Hederagenin has significant biological activity, as enhanced metabolism, immunomodulating, and the activity of cardiovascular, nerve and enzyme system and antiinflammatory, antibacterial, the effect such as antiviral, antitumor.The development of Chinese medicine separating and purifying technology in recent years, for Caulis Hederae Sinensis provides larger space in Chinese traditional treatment and Chinese patent medicine Application and preparation field.
Volatile oil is also referred to as quintessence oil, and as a kind of active component of plant, its composition is comparatively complicated, and effect is also different.The medical practice of ancient Chinese has found that volatile oil has wind dispelling, anthelmintic, eliminates the phlegm, stomach invigorating, relieving asthma, cough-relieving, the medical value such as antipyretic-antalgic and anti-inflammation.In recent years the pharmacological research of volatile oil is shown: volatile oil also has antiallergic, enzyme level, mutation, anticancer, many pharmacologically actives and the purposes such as antiviral and calm nervus centralis.
Caulis Hederae Sinensis is enriched in china natural resources, but not high to its utilization ratio at present, mainly as the green plants climbed.At present, the Chinese patent medicine for the treatment of respiratory tract disease generally adopts kinds of traditional Chinese medicines material to be used as medicine, containing more non-effective material.Numerous medical materials and component make the pharmacological action of relevant Chinese patent medicine be difficult to clearly, are difficult in addition work out Quality of Chinese Traditional Proprietary Medicine standard and quality control standard, are unfavorable for monitoring and the large-scale production of Chinese patent medicine product quality.In addition, although Caulis Hederae Sinensis extract in Europe clinical practice for many years, in the bronchitis etc. for the treatment of respiratory tract disease, also show good curative effect, but there is the higher problem of its untoward reaction rate simultaneously.One that carries out people such as S. Fazio in the evaluation of Caulis Hederae Sinensis extract safety and curative effect, the incidence rate of its untoward reaction reaches 2.7%, and this is mainly because the cilium that Caulis Hederae Sinensis blade exists can cause people's functional gastrointestinal disorder and skin allergy.
Summary of the invention
The object of the invention is to overcome above deficiency, a kind of medicine for the treatment of bronchitis, pneumonia and asthma is provided, it adopts the effective site extracted from Caulis Hederae Sinensis to be used as medicine: adopt Volatile Oil from Hedera nepalensis var. sinensis and Hederagenin to be mixed, make described medicine have the safety of more significant curative effect and Geng Gao.Another object of the present invention is, provides a kind of preparation method of described medicine, the Hederagenin obtained by alcoholic solution extraction, purification by macroporous resin, and not only active constituent content is high, and energy removal can cause the cilium of untoward reaction; In addition, add the Volatile Oil from Hedera nepalensis var. sinensis with antiinflammatory, antibacterial pharmacologically active, soft capsule or oral liquid can be made for actual therapeutic, the diseases such as bronchitis, pneumonia and asthma can be treated.
For achieving the above object, this invention takes following technical scheme.
A kind of medicine for the treatment of bronchitis, pneumonia and asthma, it is characterized in that, containing volatile oil and saponin two effective parts, described volatile oil is Volatile Oil from Hedera nepalensis var. sinensis, described saponin is Hederagenin, is by volume mixed mass ratio (mL:g) 1:40 ~ 100 by described Volatile Oil from Hedera nepalensis var. sinensis and Hederagenin.
For realizing above-mentioned second object, this invention takes following technical scheme.
Treat a preparation method for the medicine of bronchitis, pneumonia and asthma, comprise following steps: it is characterized in that:
(1) Volatile Oil from Hedera nepalensis var. sinensis is prepared
Take the stem and leaf of Caulis Hederae Sinensis, Caulis Hederae Sinensis stem and leaf and water is added by mass volume ratio 1:1 ~ 3 in extraction-rectification coupling apparatus, backflow, the light brown clear oil reservoir (volatile oil) occurred after collecting backflow also adds a small amount of natrium carbonicum calcinatum wherein and removes a little moisture, obtained Volatile Oil from Hedera nepalensis var. sinensis;
(2) Hederagenin is prepared
Take the stem and leaf of Caulis Hederae Sinensis, extract in still by mass volume ratio 1:3 ~ 10 of Caulis Hederae Sinensis stem and leaf and alcoholic solution by purity be 10 ~ 90% alcoholic solution reflux, extract, filter after reflux, extract, centrifugal, concentrating under reduced pressure, revolves steaming to extractum shape; With deionized water dissolving, cross macroporous resin column, use water and alcoholic solution eluting successively; By ethanol elution concentrating under reduced pressure (revolving steaming), 60 DEG C of vacuum dryings, weigh, obtained Hederagenin (extract);
(3) effective site component is prepared
Hederagenin obtained with step (2) for Volatile Oil from Hedera nepalensis var. sinensis obtained for step (1) is by volume mixed mass ratio (mL:g) 1:40 ~ 100, makes drug effective region component;
(4) medicine of preparation treatment bronchitis, pneumonia and asthma
1. effective site component mix homogeneously step (3) obtained, makes the soft capsule for the treatment of bronchitis, pneumonia and asthma;
2. effective site component mix homogeneously step (3) obtained, makes the oral liquid for the treatment of bronchitis, pneumonia and asthma.
Further, the macroporous resin column described in step (2) is HZ-816 macroporous resin column.
Further, the backflow described in step (2) at least carries out twice, and reflux extracting time is 1 ~ 4 hour for the first time, and second time reflux extracting time is 0.5 ~ 3 hour.
The Caulis Hederae Sinensis (Hedera nepalensis var. sinensis) that the present invention adopts, it is Araliaceae Hedera plant, have another name called soil drum rattan, bore sky wind, Radix Parthenocissi Heterophyllae, fall apart GUFENG, Radix Dendropanacis rattan, its stem and leaf are conventional Chinese medicine, there is effect of expelling wind and removing dampness, promoting blood circulation and detumescence, suppressing the hyperactive liver removing toxic substances, be usually used in the traditional Chinese medical science treatment rheumatic arthritis, lumbago, traumatic injury, hepatitis, dizziness, mouth eye snail tiltedly, epistaxis, corneal nebula, acute conjunctivitis, oedema due to nephritis, amenorrhea, swollen ulcer drug, urticaria, the disease such as eczema.
Good effect of the present invention is:
(1) provide a kind of medicine for the treatment of bronchitis, pneumonia and asthma, it adopts the effective site extracted from Caulis Hederae Sinensis: Volatile Oil from Hedera nepalensis var. sinensis and Hederagenin are mixed, and described medicine has positive effect to treatment bronchitis, pneumonia and asthma.
(2) present invention also offers a kind of preparation method of described medicine, the Hederagenin obtained by alcoholic solution extraction, purification by macroporous resin, not only active constituent content is high, and energy removal can cause the cilium of untoward reaction; In addition, add the Volatile Oil from Hedera nepalensis var. sinensis with antiinflammatory, antibacterial pharmacologically active, preparation method is simple, convenient, and reliable, can make Caulis Hederae Sinensis soft capsule or oral liquid for diseases such as actual therapeutic bronchitis, pneumonia and asthma.
(3) preparation method of the present invention is convenient to work out Quality of Chinese Traditional Proprietary Medicine standard and quality control standard aborning, is conducive to quality monitoring and the large-scale production of Chinese patent medicine product.In addition, energy removal can cause the cilium on the Caulis Hederae Sinensis blade of untoward reaction, can reduce and eliminate the untoward reaction after medication.
Accompanying drawing explanation
Fig. 1 is a kind of FB(flow block) for the treatment of the preparation method of the medicine of bronchitis, pneumonia and asthma of the present invention.
Fig. 2 is the uv absorption spectra of reference substance solution.
Fig. 3 is the uv absorption spectra of the need testing solution of the embodiment of the present invention 1.
Fig. 4 is the high-efficient liquid phase chromatogram of reference substance solution.
Fig. 5 is the high-efficient liquid phase chromatogram of the need testing solution of the embodiment of the present invention 1.
Detailed description of the invention
Below introduce a kind of detailed description of the invention for the treatment of the medicine of bronchitis, pneumonia and asthma and preparation method thereof of the present invention, provide 5 embodiments and 1 Application Example to explain the application in treatment bronchitis, pneumonia and asthma disease of preparation method and analyzing detecting method and the medicine prepared by checking in detail.But it may be noted that enforcement of the present invention is not limited to following embodiment.
embodiment 1
Treat a preparation method for the medicine of bronchitis, pneumonia and asthma, comprise following steps (see Fig. 1):
(1) Volatile Oil from Hedera nepalensis var. sinensis is prepared
Caulis Hederae Sinensis medical material (stem of Caulis Hederae Sinensis and leaf) is pulverized, then in extraction-rectification coupling apparatus, Caulis Hederae Sinensis medical material and the 20kg water of 10kg pulverizing is added by mass volume ratio 1:2, reflux, the light brown clear oil reservoir (volatile oil) occurred after collecting backflow also adds a small amount of natrium carbonicum calcinatum wherein and removes a little moisture (controlling the addition of natrium carbonicum calcinatum by the requirement of removing moisture), obtains Volatile Oil from Hedera nepalensis var. sinensis 2.8mL.
It should be noted that, the extraction-rectification coupling apparatus of employing is the device of applicant unit designed, designed, mainly comprises heater, extraction pot, rectifying column, condenser, oil-water separation extractor five parts.The entirety of device is based on 316L stainless steel.Heater wherein adopts electric heating steam generator, and heating power is 3000W, and quantity of steam controls at 0.2-0.5Mpa.Described heater is connected with the interlayer of sidewall with bottom described extraction pot by pipeline.Described rectifying column height is 1000mm, and internal diameter is 80mm, and the θ ring filler of φ=2.5mm is equipped with in its inside.The outer layer covers of described rectifying column has asbestos material and tinfoil to increase heat insulation effect.Described extraction pot height 700mm, internal diameter 300mm, volume is about 40L.Steam is heated by extraction pot interlayer.Described extraction pot inside is provided with the dividing plate of uniform pore openings, can realize rectification in rectification waterborne and water by controlling amount of water.Described condenser height is 450mm, internal diameter 20mm.Condenser external is cylindrical, and inside is equipped with pipe bundle condenser thus can be increased condensation area.The pipework condensation area of inner pipe bundle condenser is about 0.24m
2.The agent structure height 250mm of described oil-water separation extractor, internal diameter 25mm looks cup, by collecting volatile oil depending on the arm of cup bottom.Connected by a U-shaped pipe and rectifying column at the bottom welding looking cup lower-lying metal flange.By the valve below U-shaped pipe, can water be greater than to density and extract incomplete volatile oil and again extract.
(2) Hederagenin is prepared
Caulis Hederae Sinensis medical material (stem of Caulis Hederae Sinensis and leaf) is pulverized, then take Caulis Hederae Sinensis medical material that 10kg pulverizes and extract the alcoholic solution reflux, extract, twice with 60% in still, the mass volume ratio of Caulis Hederae Sinensis medical material and alcoholic solution is respectively 1:5(first time and refluxes solid-liquid ratio) and 1:3(to reflux for the second time solid-liquid ratio), first time backflow 3 hours, second time backflow 1.5 hours; Filter after reflux, extract, centrifugal, concentrating under reduced pressure, revolves and steams to extractum shape; With deionized water dissolving, cross HZ-816 macroporous resin column, then use water and ethanol elution successively; Finally ethanol elution is revolved steaming, 60 DEG C of vacuum dryings, weigh, obtained Hederagenin (extract) 157.0g.
3) effective site component is prepared
Hederagenin (extract) the by volume mass ratio 1:56(mL:g that the Volatile Oil from Hedera nepalensis var. sinensis obtained by step (1) and step (2) obtain) be mixed and made into drug effective region component
.
the analysis of the Hederagenin extract of embodiment 1 gained is detected
1, the Hederagenin extract 500mg that precision takes embodiment 1 step (2) gained adds 20mL methanol, 1mL hydrochloric acid heating hydrolysis; Hydrolysate adds water, with chloroform extraction twice, and each 20mL, separatory, merge extractive liquid, recycling design is to dry; Residue adds dissolve with methanol, standardize solution, obtained 5mg/mL need testing solution.
2, precision takes helexin reference substance (molecular formula is C
30h
48o
4) appropriate, with dissolve with methanol, be mixed with reference substance solution.
3, detection is analyzed
(1) draw need testing solution and reference substance solution respectively, water-bath volatilizes, and adds perchloric acid colour developing, and retinue reagent does blank, and scan in 190 ~ 600nm wave-length coverage, their chromatogram as depicted in figs. 1 and 2.The uv absorption spectra (see Fig. 2) of reference substance solution and uv absorption spectra (see Fig. 3) display of need testing solution: reference substance solution and need testing solution all have absorption maximum at 405nm place.Selected 405nm, for measuring wavelength, adopts ultraviolet spectrophotometry to detect: take absorbance as vertical coordinate, concentration is abscissa, drawing standard curve, measures total saponin content in the Hederagenin extract of embodiment 1 step (2) gained.
(2) need testing solution and reference substance solution is drawn respectively, (Inertsil ODS-SP C18 post under selected chromatographic condition; Mobile phase: acetonitrile-water (80:20, v/v); Column temperature: 30 DEG C; Flow velocity: 1mL/min; Determined wavelength: 210nm), injection liquid chromatography is analyzed.Take peak area as vertical coordinate, quality is abscissa, drawing standard curve, and measuring disaccharidase chain Hederagenin C(molecular formula in the Hederagenin extract of embodiment 1 step (2) gained is C
59h
960
26) content.The high-efficient liquid phase chromatogram of reference substance solution is see Fig. 4, and the high-efficient liquid phase chromatogram of need testing solution is see Fig. 5.
(3) testing result is analyzed
Analyze the result detected to show:
In the Hederagenin extract of embodiment 1 step (2) gained, Caulis Hederae Sinensis total saponin content is 81.63%.
In the Hederagenin extract of embodiment 1 step (2) gained, Hederagenin C(molecular formula is C
59h
960
26) content be 32.25%.
embodiment 2
Treat a preparation method for the medicine of bronchitis, pneumonia and asthma, comprise following steps:
(1) Volatile Oil from Hedera nepalensis var. sinensis is prepared
Caulis Hederae Sinensis medical material is pulverized, then in extraction-rectification coupling apparatus, Caulis Hederae Sinensis medical material and the 30kg water of 10kg pulverizing is added by mass volume ratio 1:3, reflux, the light brown clear oil reservoir (volatile oil) occurred after collecting backflow also adds a small amount of natrium carbonicum calcinatum wherein and removes a little moisture (controlling the addition of natrium carbonicum calcinatum by the requirement of removing moisture), obtains Volatile Oil from Hedera nepalensis var. sinensis 2.5mL.
(2) Hederagenin is prepared
Caulis Hederae Sinensis medical material (stem of Caulis Hederae Sinensis and leaf) is pulverized, then take Caulis Hederae Sinensis medical material that 10kg pulverizes and extract the alcoholic solution reflux, extract, twice with 10% in still, the mass volume ratio of Caulis Hederae Sinensis medical material and alcoholic solution is respectively 1:10(first time and refluxes solid-liquid ratio) and 1:5(to reflux for the second time solid-liquid ratio), first time backflow 4 hours, second time backflow 3 hours; Filter after reflux, extract, centrifugal, concentrating under reduced pressure, revolves and steams to extractum shape; With deionized water dissolving, cross HZ-816 macroporous resin column, then use water and ethanol elution successively; Finally ethanol elution is revolved steaming, 60 DEG C of vacuum dryings, weigh, obtained Hederagenin (extract) 167.5g.
embodiment 3
Treat a preparation method for the medicine of bronchitis, pneumonia and asthma, comprise following steps:
(1) Volatile Oil from Hedera nepalensis var. sinensis is prepared
Caulis Hederae Sinensis medical material is pulverized, then in extraction-rectification coupling apparatus, Caulis Hederae Sinensis medical material and the 10kg water of 10kg pulverizing is added by mass volume ratio 1:1, reflux, the light brown clear oil reservoir (volatile oil) occurred after collecting backflow also adds a small amount of natrium carbonicum calcinatum wherein and removes a little moisture, obtained Volatile Oil from Hedera nepalensis var. sinensis 2.9mL.
(2) Hederagenin is prepared
Caulis Hederae Sinensis medical material (stem of Caulis Hederae Sinensis and leaf) is pulverized, then take Caulis Hederae Sinensis medical material that 10kg pulverizes and extract the alcoholic solution reflux, extract, twice with 90% in still, the mass volume ratio of Caulis Hederae Sinensis medical material and alcoholic solution is respectively 1:5(first time and refluxes solid-liquid ratio) and 1:3(to reflux for the second time solid-liquid ratio), first time backflow 1 hour, second time backflow 0.5 hour; Filter after reflux, extract, centrifugal, concentrating under reduced pressure, revolves and steams to extractum shape; With deionized water dissolving, cross HZ-816 macroporous resin column, then use water and ethanol elution successively; Finally ethanol elution is revolved steaming, 60 DEG C of vacuum dryings, weigh, obtained Hederagenin (extract) 171.0g.
embodiment 4
The Volatile Oil from Hedera nepalensis var. sinensis 2.8mL that accurate extraction embodiment 1 step (1) is obtained, precision takes the obtained Hederagenin extract 157g of embodiment 1 step (2) and Cera Flava 40g, soybean phospholipid 10g, ethylparaben 1g is for subsequent use.
Described Cera Flava and soybean phospholipid are melted in 500mL PEG-4000; Add the obtained Hederagenin extract of the obtained Volatile Oil from Hedera nepalensis var. sinensis of embodiment 1 step (1), embodiment 1 step (2) and the abundant ground and mixed of ethylparaben again, make the medicinal liquid of modest viscosity, good fluidity.
Take water, gelatin and glycerol according to weight ratio 3:3:1 to pour in glue tank and be uniformly mixed at 60 DEG C of temperature, make gelatin solution; Then, institute's gelatine solution and described medicinal liquid are added in pellet press respectively, adjustment dose and rubber thickness, pelleting, dry, make the Volatile Oil from Hedera nepalensis var. sinensis of embodiment 1 extraction and the soft capsule of Hederagenin.
embodiment 5
The Volatile Oil from Hedera nepalensis var. sinensis 2.8mL that accurate extraction embodiment 1 step (1) is obtained, precision takes the obtained Hederagenin extract 157g of embodiment 1 step (2), mix homogeneously; Then add tween 80 100g, then add distilled water until medicinal liquid cumulative volume is 2L, stir, use Na
2cO
3regulate pH to 6.8, make Caulis Hederae Sinensis oral liquid.
Containing the volatile oil corresponding to 5g Caulis Hederae Sinensis medical material and saponin, i.e. 1.4 μ L Volatile Oil from Hedera nepalensis var. sinensis and 78.5mg Hederagenin extract in described Caulis Hederae Sinensis oral liquid every milliliter (ml).
application Example 1(checking the effect to treatment bronchitis, pneumonia and asthma)
This application embodiment is for the impact on the serum of the rat of the disease that suffers with chronic bronchitis, lung tissue SOD, CAT activity of the Caulis Hederae Sinensis oral liquid verifying embodiment 5 and prepare.
(1) the copying of rat model of chronic bronchitis
SD rat is placed in 11 ~ 17 DEG C of experimental situation adaptabilities to feed one week.Then modeling is respectively organized and adopt improvement fumigation to copy chronic bronchitis animal model with reference to " medical animal experiment method ".Modeling is respectively organized totally 32 rats and be placed in special 1m
3smoke-box in, light fumigation with wood shavings, sawdust, each 50g of Nicotiana tabacum L., every day 2 times, each 30min, continue 30 days.Normal group is then placed in normal smokeless environment and raises.
(2) grouping experiment
SD rat is divided into 5 groups at random, often organizes 10, male and female half and half.
1. Normal group: gavage normal saline 10ml/kg, every day 1 time.
2. model control group: gavage normal saline 10ml/kg, every day 1 time.
3. Caulis Hederae Sinensis extract (cct) high dose group: every day dosage 0.4ml/kg gavage.
4. Caulis Hederae Sinensis extract (cct) low dose group: every day dosage 0.2ml/kg, every day gavage 1 time.
5. GUILONG KECHUANNING group (positive control medication): every day dosage 1.0g/kg, every day gavage 1 time.
Described 5 groups of all continuous gavage normal saline or medicines 21 days the 2nd day after modeling terminates.
(3) experimental result
Table 1. Caulis Hederae Sinensis oral liquid is on the impact of SOD activity in chronic bronchitis rat blood serum, lung tissue and BALF
，
note:compare with Normal group:
▲ p< 0.01; Compare with model control group:
* p< 0.05,
* p< 0.01; Compare with cct group:
△ p< 0.01; Compare with GUILONG KECHUANNING group:
# p< 0.01.
Result shows: in model control group rat blood serum, lung tissue and BALF, the equal compared with normal matched group of SOD content obviously reduces (P < 0.01).Through medicine for treatment, treat the content of SOD in the serum of each group, lung tissue and BALF all higher than model control group (P < 0.05 or P < 0.01); In the serum of Caulis Hederae Sinensis extract (cct) high dose group, lung tissue and BALF, the content of SOD is all higher than GUILONG KECHUANNING group and Caulis Hederae Sinensis extract (cct) low dose group (P < 0.01), and has no notable difference (P > 0.05) between GUILONG KECHUANNING group and Caulis Hederae Sinensis extract (cct) low dose group.
Table 2. Caulis Hederae Sinensis oral liquid is on the impact of CAT activity in chronic bronchitis rat blood serum, lung tissue and BALF
，
note:compare with Normal group:
▲ p< 0.01; Compare with model control group:
* p< 0.05,
* p< 0.01; Compare with cct low dosage low dose of group:
△ p< 0.05,
△ △ p< 0.01; Compare with GUILONG KECHUANNING group:
# p< 0.05,
## p< 0.01.
Result shows: in model control group rat blood serum, lung tissue and BALF, the equal compared with normal matched group of the content of CAT obviously reduces (P < 0.01).Through medicine for treatment, treat the content of CAT in each group of serum, lung tissue and BALF all higher than model control group (P < 0.05 or P < 0.01); In cct high dose group serum, lung tissue and BALF, the content of CAT is all higher than GUILONG KECHUANNING group and cct low dose group (P < 0.05 or P < 0.01), and has no notable difference (P > 0.05) between GUILONG KECHUANNING group and cct low dose group.
Experimental result shows: Caulis Hederae Sinensis oral liquid prepared by the present invention has positive effect to treatment bronchitis, pneumonia and asthma.
illustrate:owing to being suitable for the administering mode taking gavage or injection in zoopery, soft capsule is comparatively large due to volume, tests and is difficult to swallow with rat, therefore, soft capsule is difficult to be filled into as oral liquid in rat body, so the present invention has mainly carried out animal experiment with Caulis Hederae Sinensis oral liquid.Because the composition of Caulis Hederae Sinensis soft capsule of the present invention is consistent with the composition of Caulis Hederae Sinensis oral liquid, thus, its curative effect also should be identical.
Claims (4)
1. treat the medicine of bronchitis, pneumonia and asthma for one kind, it is characterized in that, containing volatile oil and saponin two effective parts, described volatile oil is Volatile Oil from Hedera nepalensis var. sinensis, described saponin is Hederagenin, is by volume mixed mass ratio (mL:g) 1:40 ~ 100 by described Volatile Oil from Hedera nepalensis var. sinensis and Hederagenin.
2. treat a preparation method for the medicine of bronchitis, pneumonia and asthma as claimed in claim 1, it is characterized in that, comprise following steps:
(1) Volatile Oil from Hedera nepalensis var. sinensis is prepared
Take the stem and leaf of Caulis Hederae Sinensis, Caulis Hederae Sinensis stem and leaf and water is added by mass volume ratio 1:1 ~ 3 in extraction-rectification coupling apparatus, reflux, also add a small amount of natrium carbonicum calcinatum wherein removes a little moisture to the light brown clear oil reservoir occurred after collecting backflow, obtained Volatile Oil from Hedera nepalensis var. sinensis;
(2) Hederagenin is prepared
Take the stem and leaf of Caulis Hederae Sinensis, extract in still by mass volume ratio 1:3 ~ 10 of Caulis Hederae Sinensis stem and leaf and alcoholic solution by purity be 10 ~ 90% alcoholic solution reflux, extract, filter after reflux, extract, centrifugal, concentrating under reduced pressure, revolves steaming to extractum shape; With deionized water dissolving, cross macroporous resin column, use water and alcoholic solution eluting successively; By ethanol elution concentrating under reduced pressure, 60 DEG C of vacuum dryings, weigh, obtained Hederagenin;
(3) effective site component is prepared
Hederagenin obtained with step (2) for Volatile Oil from Hedera nepalensis var. sinensis obtained for step (1) is by volume mixed mass ratio (mL:g) 1:40 ~ 100, makes drug effective region component;
(4) medicine of preparation treatment bronchitis, pneumonia and asthma
1. effective site component mix homogeneously step (3) obtained, is prepared into soft capsule;
2. effective site component mix homogeneously step (3) obtained, is prepared into oral liquid.
3. preparation method according to claim 2, is characterized in that, the macroporous resin column described in step (2) is HZ-816 macroporous resin column.
4. preparation method according to claim 2, is characterized in that, the backflow described in step (2) at least carries out twice, and reflux extracting time is 1 ~ 4 hour for the first time, and second time reflux extracting time is 0.5 ~ 3 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410556463.6A CN104306416B (en) | 2014-10-20 | 2014-10-20 | A kind of medicine for treating bronchitis, pneumonia and asthma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410556463.6A CN104306416B (en) | 2014-10-20 | 2014-10-20 | A kind of medicine for treating bronchitis, pneumonia and asthma and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104306416A true CN104306416A (en) | 2015-01-28 |
| CN104306416B CN104306416B (en) | 2017-08-04 |
Family
ID=52361825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410556463.6A Active CN104306416B (en) | 2014-10-20 | 2014-10-20 | A kind of medicine for treating bronchitis, pneumonia and asthma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306416B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114848661A (en) * | 2022-06-17 | 2022-08-05 | 广西林洋药业有限公司 | Application of pulsatilla saponin extract in preparation of medicine for treating autoimmune diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1856317A (en) * | 2003-09-19 | 2006-11-01 | 恩格哈德药物有限及两合公司 | Production method of an ivy leaf extract and extract prepared with same |
| CN101757252A (en) * | 2010-01-22 | 2010-06-30 | 承德颈复康药业集团有限公司 | Method for preparing volatile oil for Jingfukang preparation |
| CN101979117A (en) * | 2010-10-28 | 2011-02-23 | 华东理工大学 | Volatile component rectifying-extracting coupled extraction device and method |
| CN102188465A (en) * | 2011-04-18 | 2011-09-21 | 中国中医科学院中药研究所 | Preparation method of hedera plant extractives and purposes thereof |
-
2014
- 2014-10-20 CN CN201410556463.6A patent/CN104306416B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1856317A (en) * | 2003-09-19 | 2006-11-01 | 恩格哈德药物有限及两合公司 | Production method of an ivy leaf extract and extract prepared with same |
| CN101757252A (en) * | 2010-01-22 | 2010-06-30 | 承德颈复康药业集团有限公司 | Method for preparing volatile oil for Jingfukang preparation |
| CN101979117A (en) * | 2010-10-28 | 2011-02-23 | 华东理工大学 | Volatile component rectifying-extracting coupled extraction device and method |
| CN102188465A (en) * | 2011-04-18 | 2011-09-21 | 中国中医科学院中药研究所 | Preparation method of hedera plant extractives and purposes thereof |
Non-Patent Citations (2)
| Title |
|---|
| 童星: "中华常春藤中皂苷类成分和挥发油分离分析研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 童星等: "常春藤挥发油的提取及GC-MS分析", 《精细化工》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114848661A (en) * | 2022-06-17 | 2022-08-05 | 广西林洋药业有限公司 | Application of pulsatilla saponin extract in preparation of medicine for treating autoimmune diseases |
| CN114848661B (en) * | 2022-06-17 | 2024-05-17 | 广西林洋药业有限公司 | Application of pulsatilla chinensis saponin extract in preparation of medicine for treating autoimmune diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104306416B (en) | 2017-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101156906B (en) | A pueraria root scutellaria and coptis medicinal composition | |
| CN105106816B (en) | Protect the traditional Chinese medicine health care product preparation and preparation method thereof of chemical damage | |
| CN104306416A (en) | Medicine for treating bronchitis, pneumonia and asthma and preparation method thereof | |
| Eum et al. | Anti-inflammatory activity of CML-1: an herbal formulation | |
| CN104491048B (en) | A kind of loquat leaf total sesquiterpene glucoside extract and preparation method and application | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN105748601A (en) | Method for extracting Cistanche deserticola and Cistanche deserticola health product | |
| CN105535146B (en) | Pretreatment method of radix puerariae, radix scutellariae and rhizoma coptidis composition medicinal materials | |
| CN102343021A (en) | New process method for preparing Guifudihuang capsule | |
| CN104524273A (en) | Preparation method of Yinqiao preparation | |
| CN102362916B (en) | Traditional Chinese medicinal compound extract product for protecting liver and preparation method thereof | |
| CN108497246A (en) | A kind of plant weight losing function beverage and preparation method thereof | |
| CN104474040B (en) | Traditional Chinese medicine composition with effect of preventing and treating migraine as well as preparation method and application thereof | |
| CN102940724A (en) | Preparation method of traditional Chinese medicine compound capsule for diminishing inflammation | |
| CN108440477B (en) | A method of preparing Quercetin from tungoiltree juvenile leaf | |
| CN105748628A (en) | Traditional Chinese medicine soluble powder for treating piglet diarrhea | |
| CN105727104A (en) | Medicine composition with effects of diminishing inflammation and relieving cough and method for preparing medicine composition | |
| CN104815011A (en) | Mongolian medicine piper longum extract used for reducing blood fat | |
| CN105168328A (en) | Kudzuvine root extract, extracting method and dropping pill of kudzuvine root extract | |
| CN105477361A (en) | Preparation method and preparation of traditional Chinese medicinal composition for treating gastritis | |
| CN105079174B (en) | A kind of tonic tablet for kidney-reinforcing and preparation method thereof | |
| CN1919273B (en) | Chinese medicinal composition for treating headache | |
| CN102274254B (en) | Preparation method of alligator alternanthera effective fraction extract | |
| CN113679653B (en) | Application of dendrobium officinale leaf total alkaloids in preparation of cosmetics | |
| CN108721343B (en) | Medicine formula for treating presenile dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150128 Assignee: Zhejiang CONBA Pharmaceutical Co., Ltd. Assignor: East China University of Science and Technology Contract record no.: 2016310000013 Denomination of invention: Medicine for treating bronchitis, pneumonia and asthma and preparation method thereof License type: Exclusive License Record date: 20160303 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160518 Address after: 323400 No. 150 West Ring Road, Songyang County, Zhejiang Province, China Applicant after: Zhejiang CONBA Pharmaceutical Co., Ltd. Address before: 200237 Meilong Road, Shanghai, No. 130, No. Applicant before: East China University of Science and Technology |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |